Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · IEX Real-Time Price · USD
1.170
-0.010 (-0.85%)
At close: Jul 19, 2024, 4:00 PM
1.080
-0.090 (-7.69%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Adaptimmune Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ADAP stock have an average target of 4.29, with a low estimate of 1.00 and a high estimate of 10. The average target predicts an increase of 266.67% from the current stock price of 1.17.
Analyst Consensus: Buy
* Price targets were last updated on May 30, 2024.
Analyst Ratings
The average analyst rating for ADAP stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 0 | 0 | 0 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Initiates $3.15 | Buy | Initiates | $3.15 | +169.23% | May 30, 2024 |
| Mizuho | Mizuho | Strong Buy Maintains $9 → $3 | Strong Buy | Maintains | $9 → $3 | +156.41% | May 17, 2024 |
| EF Hutton | EF Hutton | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +754.70% | Aug 10, 2023 |
| Barclays | Barclays | Sell Maintains $2 → $1 | Sell | Maintains | $2 → $1 | -14.53% | Aug 10, 2023 |
| EF Hutton | EF Hutton | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +754.70% | Jun 5, 2023 |
Financial Forecast
Revenue This Year
63.22M
from 60.28M
Increased by 4.87%
Revenue Next Year
47.78M
from 63.22M
Decreased by -24.42%
EPS This Year
-0.56
from -0.54
EPS Next Year
-0.59
from -0.56
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 104.4M | 110.8M | 96.1M | 192.7M | 280.7M |
| Avg | 63.2M | 47.8M | 56.5M | 122.5M | 194.5M |
| Low | 23.2M | 11.8M | 26.8M | 68.6M | 112.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 73.2% | 75.2% | 101.1% | 240.7% | 129.1% |
| Avg | 4.9% | -24.4% | 18.3% | 116.6% | 58.8% |
| Low | -61.5% | -81.3% | -44.0% | 21.3% | -8.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.15 | -0.25 | -0.61 |
| Avg | -0.56 | -0.59 | -0.68 |
| Low | -0.75 | -0.78 | -0.74 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.